Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 6 | 258,618 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
21 Form 4 filings on record, the earliest from Apr 8, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Grant or award | Common Stock | 43,103 | $0.00 | - | ||
| Grant or award | Common Stock | 43,103 | $0.00 | - | ||
| Grant or award | Common Stock | 43,103 | $0.00 | - | ||
| Grant or award | Common Stock | 43,103 | $0.00 | - | ||
| Nathan Fischel - Director | Grant or award | Common Stock | 43,103 | $0.00 | - | |
| Grant or award | Common Stock | 43,103 | $0.00 | - | ||
| Kimberly R. Peery - Officer | Grant or award | Stock Options -Right to Buy | 40,000 | $0.00 | - | |
| Grant or award | Common Stock | 46,948 | $0.00 | - | ||
| Grant or award | Common Stock | 46,948 | $0.00 | - | ||
| Grant or award | Common Stock | 46,948 | $0.00 | - | ||
| Nathan Fischel - Director | Grant or award | Common Stock | 46,948 | $0.00 | - | |
| Grant or award | Common Stock | 46,948 | $0.00 | - | ||
| Grant or award | Common Stock | 46,948 | $0.00 | - | ||
| Paul J. Isaac - Director | Open-market purchase | Common Stock | 10,000 | $2.18 | $22K | |
| Paul J. Isaac - Director | Open-market purchase | Common Stock | 20,000 | $2.24 | $45K | |
| Grant or award | Common Stock | 43,668 | $0.00 | - | ||
| Nathan Fischel - Director | Grant or award | Common Stock | 43,668 | $0.00 | - | |
| Grant or award | Common Stock | 43,668 | $0.00 | - | ||
| Grant or award | Common Stock | 43,668 | $0.00 | - | ||
| Grant or award | Common Stock | 43,668 | $0.00 | - | ||
| Grant or award | Common Stock | 43,668 | $0.00 | - | ||
| Kimberly R. Peery - Officer | Grant or award | Stock Options -Right to Buy | 50,000 | $0.00 | - |
Stereotaxis, Inc. (STXS) had 6 insider filings in the last 90 days, with the most recent on 2026-07-01. The full record for STXS runs to 21 Form 4 filings, the earliest from 2025-04-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of STXS were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of STXS were filed in the last 90 days.
This page tracks STXS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add STXS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.